# NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.

> **NCT04861181** · PHASE4 · TERMINATED · sponsor: **Hospices Civils de Lyon** · enrollment: 12 (actual)

## Conditions studied

- Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer

## Interventions

- **BIOLOGICAL:** Pharmacokinetics, Dosage of Niraparib

## Key facts

- **NCT ID:** NCT04861181
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-05
- **Primary completion:** 2025-04-17
- **Final completion:** 2025-04-17
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** End of inclusion period.
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04861181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04861181, "NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04861181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*